| Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint GL Drusano, SL Preston, C Hardalo, R Hare, C Banfield, D Andes, ... Antimicrobial agents and chemotherapy 45 (1), 13-22, 2001 | 284 | 2001 |
| Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases AF Zuluaga, BE Salazar, CA Rodriguez, AX Zapata, M Agudelo, O Vesga BMC infectious diseases 6, 1-10, 2006 | 233 | 2006 |
| Staphylococcus aureus Small Colony Variants Are Induced by the Endothelial Cell Intracellular Milieu O Vesga, MC Groeschel, MF Otten, DW Brar, JM Vann, RA Proctor Journal of Infectious Diseases 173 (3), 739-742, 1996 | 225 | 1996 |
| In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria ML Van Ogtrop, D Andes, TJ Stamstad, B Conklin, WJ Weiss, WA Craig, ... Antimicrobial agents and chemotherapy 44 (4), 943-949, 2000 | 211 | 2000 |
| Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. RA Proctor, JM Balwit, O Vesga Infectious agents and disease 3 (6), 302-312, 1994 | 195 | 1994 |
| Etiologic diagnosis of chronic osteomyelitis: a prospective study AF Zuluaga, W Galvis, JG Saldarriaga, M Agudelo, BE Salazar, O Vesga Archives of internal medicine 166 (1), 95-100, 2006 | 187 | 2006 |
| Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator O Vesga, M Agudelo, BE Salazar, CA Rodriguez, AF Zuluaga Antimicrobial agents and chemotherapy 54 (8), 3271-3279, 2010 | 148 | 2010 |
| Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study AF Zuluaga, W Galvis, F Jaimes, O Vesga BMC infectious diseases 2, 1-7, 2002 | 140 | 2002 |
| Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics AF Zuluaga, M Agudelo, CA Rodriguez, O Vesga BMC Clinical Pharmacology 9, 1-11, 2009 | 107 | 2009 |
| Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model AF Zuluaga, M Agudelo, JJ Cardeño, CA Rodriguez, O Vesga PloS one 5 (5), e10744, 2010 | 71 | 2010 |
| In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin CA Rodriguez, M Agudelo, AF Zuluaga, O Vesga BMC infectious diseases 10, 1-12, 2010 | 65 | 2010 |
| Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model CA Rodriguez, M Agudelo, AF Zuluaga, O Vesga Antimicrobial agents and chemotherapy 56 (1), 243-247, 2012 | 50 | 2012 |
| Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole M Agudelo, O Vesga Antimicrobial agents and chemotherapy 56 (5), 2659-2665, 2012 | 49 | 2012 |
| Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia CA Rodriguez, M Agudelo, JC Cataño, AF Zuluaga, O Vesga Journal of Infection 59 (4), 277-280, 2009 | 44 | 2009 |
| Optimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae AV Restrepo, BE Salazar, M Agudelo, CA Rodriguez, AF Zuluaga, ... BMC microbiology 5, 1-8, 2005 | 39 | 2005 |
| Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem M Agudelo, CA Rodriguez, CA Pelaez, O Vesga Antimicrobial agents and chemotherapy 58 (2), 1005-1018, 2014 | 37 | 2014 |
| Staphylococcus aureus resistente a vancomicina CA Rodríguez, O Vesga Biomédica 25 (4), 575-587, 2005 | 36 | 2005 |
| In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products CA Rodriguez, M Agudelo, AF Zuluaga, O Vesga International journal of antimicrobial agents 49 (2), 189-197, 2017 | 25 | 2017 |
| Activity of levofloxacin against penicillin-resistant Streptococcus pneumoniae in normal and neutropenic mice O Vesaga Abstracts of 36th Interscience Conference on Antimicrobial Agents and …, 1996 | 25 | 1996 |
| Staphylococcus aureus small colony variants cause persistent and resistant infections RA Proctor, OV Vesga, MF Otten, SP Koo, MR Yeaman, HG Sahl, ... Chemotherapy 42 (Suppl. 2), 47-52, 1996 | 25 | 1996 |
